Clinical trial CheckMate
A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 459)
| Cancers | |
|---|---|
| Organ | Liver |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | BMS - Bristol Myers Squibb int. |
| EudraCT Identifier | 2015-002740-13 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02576509 |
| Inclusion criteria | Not eligible for surgery |
| Last update |